Empowering AI assisted clinical drug development: tactics to address data bias, the digital divide and missing patient populations through AI and digital solutions - Scorecard - MDSpire
Clinical Scorecard: Enhancing Clinical Drug Development with AI: Strategies to Mitigate Data Bias, Bridge the Digital Divide, and Include Underrepresented Patient Groups
At a Glance
Category
Detail
Condition
Clinical Drug Development
Key Mechanisms
Utilization of AI methodologies to enhance patient representation and mitigate data bias in clinical trials.
Target Population
Underrepresented demographic groups in clinical trials.
Care Setting
Clinical trial design and implementation.
Key Highlights
AI can accelerate clinical trials by identifying suitable patient cohorts.
Current datasets often lack representation from diverse populations.
Biases in data can lead to incomplete models and affect trial outcomes.
Strategies are needed to enhance patient engagement and data inclusivity.
Ethical considerations must be addressed in the use of AI in drug development.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Data biases may lead to ineffective predictive models.
Lack of representation can affect the generalizability of trial results.
Patient & Prescribing Data
Patients from diverse genetic, socioeconomic, and environmental backgrounds.
Inclusion of varied demographic data is crucial for precision medicine.
Clinical Best Practices
Enhance dataset heterogeneity to improve predictive accuracy.
Implement AI-driven techniques for better trial design.
Focus on inclusivity in patient representation during trials.
